Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22alpha-targeted overexpression of the serotonin transporter.
about
Molecular Mechanisms of Pulmonary Vascular Remodeling in Pulmonary Arterial HypertensionEmerging concepts in the molecular basis of pulmonary arterial hypertension: part I: metabolic plasticity and mitochondrial dynamics in the pulmonary circulation and right ventricle in pulmonary arterial hypertensionHIF-1 inhibition decreases systemic vascular remodelling diseases by promoting apoptosis through a hexokinase 2-dependent mechanismThe cancer theory of pulmonary arterial hypertension.Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapiesNew trial designs and potential therapies for pulmonary artery hypertension.Lung ¹⁸F-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring of pulmonary arterial hypertensionUp-regulation of hexokinase1 in the right ventricle of monocrotaline induced pulmonary hypertension.Autocrine fibroblast growth factor-2 signaling contributes to altered endothelial phenotype in pulmonary hypertension.Inhibition of fatty acid synthase is protective in pulmonary hypertension.Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodents.Hyperoxia synergizes with mutant bone morphogenic protein receptor 2 to cause metabolic stress, oxidant injury, and pulmonary hypertension.Genome-wide association analysis identifies a susceptibility locus for pulmonary arterial hypertension.New therapies for pulmonary arterial hypertension: an update on current bench to bedside translation.Mechanisms of disease: pulmonary arterial hypertension.Rodent models of pulmonary hypertension: harmonisation with the world health organisation's categorisation of human PH.Anticipated classes of new medications and molecular targets for pulmonary arterial hypertensionTherapeutic applications of dichloroacetate and the role of glutathione transferase zeta-1.The role of nuclear factor of activated T cells in pulmonary arterial hypertension.Pulmonary arterial hypertension - progress in understanding the disease and prioritizing strategies for drug development.Metabolism and bioenergetics in the right ventricle and pulmonary vasculature in pulmonary hypertension.Increased Pyruvate Dehydrogenase Kinase 4 Expression in Lung Pericytes Is Associated with Reduced Endothelial-Pericyte Interactions and Small Vessel Loss in Pulmonary Arterial Hypertension.Translating Research into Improved Patient Care in Pulmonary Arterial Hypertension.Emerging Therapeutics in Pulmonary Hypertension.Proinflammatory Signature of the Dysfunctional Endothelium in Pulmonary Hypertension. Role of the Macrophage Migration Inhibitory Factor/CD74 Complex.Inhibition of gut- and lung-derived serotonin attenuates pulmonary hypertension in mice.[The cancer paradigm in pulmonary arterial hypertension: towards anti-remodeling therapies targeting metabolic dysfunction?]Pyruvate dehydrogenase inhibition by the inflammatory cytokine TNFα contributes to the pathogenesis of pulmonary arterial hypertension.
P2860
Q28067063-700DAC37-7622-47D8-9E43-62418803DC73Q28083183-C1F71E59-0DAF-49F1-92D5-3FBCC5D81F67Q28583933-88436F75-173A-488B-B902-0175DEC03581Q33788493-7C157724-7CED-4B38-A782-1ED3DCA9F4FBQ33849207-4425A0D8-977B-45C2-936F-0C1BD4C94738Q33982467-0B15F75A-636B-4098-BD63-C03801CFE515Q34127884-9EC324EE-908D-46D4-AD91-3B3FFC569D6CQ34346381-2721D4E9-AADC-45E2-AEA5-8E5A3C908DBAQ36805200-FBDAEA37-CA3B-4974-ACD9-62FC90D98828Q36941262-05FBD830-390F-4BEE-8ED9-21FEE38D5239Q37217507-5AACF168-2FC7-4EE1-94B3-FF611DC43471Q37410202-894E086F-9DFA-4158-B444-253AA1A2973EQ37596437-E06DE505-C8F7-4B9E-8F31-2368ED60ED34Q37698113-EC3C40A0-81B8-4518-9944-97E60F94C230Q37724192-9A1FF3C6-456B-49E0-B639-EDD37141AACCQ37892336-12A92E26-E11F-42C5-A786-CDFB7911CB57Q37898745-FF0B4F6D-46CB-47FD-91ED-325AE4320D43Q38105550-C0D245B2-0CD7-4329-8484-9FAFE0B3C0B6Q38988403-763C4DF0-625C-41A5-8C2C-16E5A813EBDAQ39095141-5796FCDB-1DBB-43D1-9478-BF863E3423F4Q39317865-5D88DB7E-F73B-4E81-B8A0-503DDAD037C6Q40302879-6AEA99A1-956E-4454-AB52-6CE75AC68BC7Q41022731-D7B6D4E3-9098-4506-B16A-178675C50918Q46682354-CB22A5A9-A130-4B8F-B525-942758825D49Q47700134-AA528124-EFA3-4F8D-B214-70DFBE362D9FQ48155147-4B6A2B7D-CDC0-4BDD-BC28-641E9C3244FDQ48439804-B03361BA-6ABA-4118-A987-502574DF3795Q52312423-BDB6744B-9B83-45A9-9308-E334617C94B5Q54570348-D833B3F3-3471-4FF1-8F54-7A9F75ACD5A1
P2860
Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22alpha-targeted overexpression of the serotonin transporter.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Dichloroacetate treatment part ...... of the serotonin transporter.
@en
Dichloroacetate treatment part ...... of the serotonin transporter.
@nl
type
label
Dichloroacetate treatment part ...... of the serotonin transporter.
@en
Dichloroacetate treatment part ...... of the serotonin transporter.
@nl
prefLabel
Dichloroacetate treatment part ...... of the serotonin transporter.
@en
Dichloroacetate treatment part ...... of the serotonin transporter.
@nl
P2093
P50
P921
P356
P1433
P1476
Dichloroacetate treatment part ...... n of the serotonin transporter
@en
P2093
Elie Fadel
Laurence Dewachter
Mohamed Izikki
Patricia Zadigue
Saadia Eddahibi
Serge Adnot
P304
P356
10.1096/FJ.09-131664
P407
P577
2009-08-13T00:00:00Z